Update on GSK’S MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Non-Small Cell Lung Cancer

[Business Wire] – Agenus Inc. today announced that GlaxoSmithKline’s MAGRITi study, a Phase 3 randomized, blinded, placebo-controlled MAGE-A3ii cancer immunotherapeutic trial in non-small cell lung cancer patients, which contains Agenus’QS-21 Stimulon® more

View todays social media effects on AGEN

View the latest stocks trending across Twitter. Click to view dashboard

See who Agenus is hiring next, click here to view